Close

Registration is free and only takes a moment. If you have already registered, please log in now.

Create Account
Forgot your password?
Log In
  • Links
  • Publisher Full Text
  • Authors
  • Milazzo L
  • Antinori S
  • MESH
  • Antibodies, Monoclonal
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Female
  • Humans
  • Hypercholesterolemia
  • Male
  • Proprotein Convertases
  • Receptors, LDL

Unbound MEDLINE

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

Links

  • Publisher Full Text

    • Authors

    Milazzo L, Antinori S

    Source

    The New England journal of medicine 366:25 2012 Jun 21 pg 2425; author reply 2426

    MeSH

    Antibodies, Monoclonal
    Anticholesteremic Agents
    Cholesterol, LDL
    Female
    Humans
    Hypercholesterolemia
    Male
    Proprotein Convertases
    Receptors, LDL

    Pub Type(s)

    Comment
    Letter

    Language

    eng

    PubMed ID

    22716983

    Related Citations

    • Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    • [Effect of a monoclonal antibody to PCSK9 on LDL cholesterol].
    • Lowering plasma cholesterol by raising LDL receptors--revisited.
    • Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
    • Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.
    • PCSK9 inhibition: the next statin?
    • An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
    • [In addition to atorvastatin. Innovative antibody lowers LDL around 72%].
    More
    unbound logo
    • Home »
    • Contact Us »
    • Help »
    • Privacy / Disclaimer »
    • Terms of Service »
    • Log In »
    • twitter
    • facebook
    © 2000–2013 Unbound Medicine, Inc. All rights reserved